In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
about
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
In chronic myeloid leukemia pa ...... erging drug-resistant mutants.
@ast
In chronic myeloid leukemia pa ...... erging drug-resistant mutants.
@en
type
label
In chronic myeloid leukemia pa ...... erging drug-resistant mutants.
@ast
In chronic myeloid leukemia pa ...... erging drug-resistant mutants.
@en
prefLabel
In chronic myeloid leukemia pa ...... erging drug-resistant mutants.
@ast
In chronic myeloid leukemia pa ...... erging drug-resistant mutants.
@en
P2093
P2860
P50
P1433
P1476
In chronic myeloid leukemia pa ...... erging drug-resistant mutants.
@en
P2093
Alessandra Iurlo
Caterina De Benedittis
Domenico Russo
Jana Linhartova
Katerina Machova Polakova
Luana Bavaro
Manuela Mancini
Michele Cavo
P2860
P2888
P356
10.1186/S12885-016-2635-0
P407
P50
P577
2016-08-02T00:00:00Z
P6179
1024143327